Zepbound and Lilly's widely used diabetes drug, Mounjaro, both chemically called tirzepatide, belong to a class of drugs ...
Zepbound (tirzepatide), manufactured by Fortune 500 firm Eli Lilly & Co., bested competitor Wegovy (semaglutide), a product of Global 500 company Novo Nordisk, in a 2023–24 randomized clinical ...
The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.
Zepbound is a medication containing tirzepatide, which the preliminary study showed to be more effective for weight loss than Wegovy, which contains semaglutide. This preliminary study ...